Links to Fileshttps://ezproxy.stevenson.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=rzh&AN=123295317&site=eds-live&scope=site
MetadataShow full item record
Type of Work2 pages
DepartmentSandra R. Berman School of Nursing and Health Professions
Citation of Original PublicationAschenbrenner, D. S. (2017). Drug watch. AJN American Journal Of Nursing, 117(6), 22-23.
The article reports on drugs that received approval from the U.S. Food and Drug Administration. It notes on the approval given to deflazacort (Emflaza) as treatment for Duchenne muscular dystrophy, the most common type of muscular dystrophy characterized by progressive muscle deterioration and weakness starting in childhood. It cites the approval given to brodalumab (Siliq) as treatment for moderate-to-severe plaque psoriasis, an autoimmune disease that causes patches of red and flaky skin.